title: A DRD2 polymorphism predicts PANSS score variability in schizophrenia patients treated with antipsychotics.
authors.forename: Joanne
authors.initials: J
authors.lastname: Voisey
authors.forename: Christopher D
authors.initials: CD
authors.lastname: Swagell
authors.forename: Ian P
authors.initials: IP
authors.lastname: Hughes
authors.forename: Mark
authors.initials: M
authors.lastname: Barnes
authors.forename: Simon C
authors.initials: SC
authors.lastname: Burton
authors.forename: Angela
authors.initials: A
authors.lastname: van Daal
authors.forename: C Phillip
authors.initials: CP
authors.lastname: Morris
authors.forename: Bruce R
authors.initials: BR
authors.lastname: Lawford
authors.forename: Ross McD
authors.initials: RM
authors.lastname: Young
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic / Q000235:genetics*; D011237:Predictive Value of Tests; D011569:Psychiatric Status Rating Scales; D017448:Receptors, Dopamine D2 / Q000235:genetics*; D012559:Schizophrenia / Q000188:drug therapy* / Q000235:genetics*; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D017448:Receptors, Dopamine D2